Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.
about
Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophyOspemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidenceOspemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data.Advances in pharmacotherapy for treating female sexual dysfunction.Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopauseEndometrial safety of ospemifene: results of the phase 2/3 clinical development program.Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial.The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophyOspemifene in the treatment of vulvovaginal atrophy.Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.Management of menopause in women with breast cancer.Emerging hormonal treatments for menopausal symptoms.Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause.Local hormone therapy for genitourinary syndrome of menopause in breast cancer patients: is it safe?Impact of Ospemifene on Quality of Life and Sexual Function in Young Survivors of Cervical Cancer: A Prospective Study.Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy.Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Vulvar vestibular effects of ospemifene: a pilot study.Effects of ospemifene on vaginal epithelium of post-menopausal women.Ospemifene: a novel selective estrogen receptor modulator for treatment of dyspareunia.Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms.Randomized, Double-Blind, Placebo-Controlled Study of Modified Erzhi Granules in the Treatment of Menopause-Related Vulvovaginal Atrophy
P2860
Q28066699-8B3CA291-8090-4B45-816E-BABB5680FBA8Q30277966-507A9A02-3FA6-495D-826F-5397D0F4FDB7Q30380010-31948CDB-B4AB-4232-81BA-1C3728FD96EBQ30491704-C21F7572-532C-4DDA-85D1-B0A5022029A1Q34465301-ECEC7FF7-F764-439C-AAD6-95FCB85B6EEDQ34532021-A9761E08-7718-40A2-ADF1-473342F91C1EQ34759968-23407BBE-83A2-420A-8E4D-B705F51A487CQ35317535-2B245670-13E9-4FC6-9C2A-147140160F2DQ35626394-CB77363B-5B6A-46C1-9AE3-5B53E4B5C519Q38194966-ED0D47C1-C483-4567-AE99-2F37205DDD96Q38232774-F5D96F7B-5C95-4618-BC02-5BEDB25CAFA1Q38298951-B87632E6-B406-4E8C-8D57-87675C6B2AE5Q38307019-9C039B80-B90D-4264-AEBB-051ED278C894Q38836000-6C9436DC-1C27-4B8A-BACF-E17DC0424592Q39170418-873E195E-CAFD-484C-9DF4-01A6AE201DB7Q41110474-A754B91F-685A-4593-9663-EB35965AD81EQ41689276-F2775C5A-DAF5-4CA9-BEE3-419D5E71305FQ45070875-3B17B0A1-8B17-44F0-96E9-D83792DAB392Q47650581-19208A12-31C4-4701-BA18-3A7BDAD6D03CQ48242249-1D752273-E936-42E2-9302-664B214ACB35Q50611000-E8B9A54F-6F1E-4A85-90DB-5EDE4A9A0924Q51105627-54D70D5C-58F4-4BA8-9AD5-DDD79B6BA0C2Q53496298-FBE40CC8-1BB2-441B-95B0-261E74870848Q58567402-6C42D694-3E38-45BB-AC17-34CE58B546D4
P2860
Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Ospemifene 12-month safety and ...... th vulvar and vaginal atrophy.
@en
Ospemifene 12-month safety and ...... th vulvar and vaginal atrophy.
@nl
type
label
Ospemifene 12-month safety and ...... th vulvar and vaginal atrophy.
@en
Ospemifene 12-month safety and ...... th vulvar and vaginal atrophy.
@nl
prefLabel
Ospemifene 12-month safety and ...... th vulvar and vaginal atrophy.
@en
Ospemifene 12-month safety and ...... th vulvar and vaginal atrophy.
@nl
P2093
P2860
P1433
P1476
Ospemifene 12-month safety and ...... th vulvar and vaginal atrophy.
@en
P2093
D J Portman
G A Bachmann
O Ylikorkala
Ospemifene Study Group
P R Koninckx
S R Goldstein
P2860
P304
P356
10.3109/13697137.2013.834493
P577
2013-11-23T00:00:00Z